Balance Sheet
Accounts PayablesCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Dr Reddys Laboratories (RDY) Payables: 2018-2025

Historic Payables for Dr Reddys Laboratories (RDY) over the last 8 years, with Mar 2025 value amounting to $862.0 million.

  • Dr Reddys Laboratories' Payables rose 64.50% to $862.0 million in Q1 2025 from the same period last year, while for Mar 2025 it was $2.5 billion, marking a year-over-year increase of 9.73%. This contributed to the annual value of $862.0 million for FY2025, which is 64.50% up from last year.
  • Per Dr Reddys Laboratories' latest filing, its Payables stood at $862.0 million for FY2025, which was up 64.50% from $524.0 million recorded in FY2024.
  • Dr Reddys Laboratories' Payables' 5-year high stood at $862.0 million during FY2025, with a 5-year trough of $412.0 million in FY2023.
  • Its 3-year average for Payables is $599.3 million, with a median of $524.0 million in 2024.
  • In the last 5 years, Dr Reddys Laboratories' Payables crashed by 40.63% in 2023 and then skyrocketed by 64.50% in 2025.
  • Dr Reddys Laboratories' Payables (Yearly) stood at $641.0 million in 2021, then grew by 8.27% to $694.0 million in 2022, then tumbled by 40.63% to $412.0 million in 2023, then rose by 27.18% to $524.0 million in 2024, then surged by 64.50% to $862.0 million in 2025.